Sir Andrew Witty is stepping down as the chief executive of GlaxoSmithKline PLC (GSK) and Emma Walmsley has been appointed as his successor. This appointment of the next head of the U.K. pharmaceutical giant gave The Man From FCPA pause to reconsider what was most probably Sir Andrew’s greatest setback during his tenure; the GSK in China scandal which led to the company being convicted of bribery and corruption of Chinese government official in the health care industry, under Chinese domestic law. The company paid a fine of nearly $498 million and had its top three China business unit officials criminally convicted for their roles in overseeing the bribery scheme. There has been no final resolution of these matters under either the U.K. Bribery Act or FCPA.
